North America Anti-Rheumatic Drug Market Size, Share, Opportunities, And Trends By Type Of Disease (Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, Others), By Drug Class (Disease-modifying Anti-Rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, JAK Inhibitor, Others), And By Sales Channel (Prescription, Over-the-counter (OTC)) - Forecasts From 2022 To 2027

North America’s antirheumatic drugs market was valued at US$122.619 billion in 2020. The market is projected to grow at a CAGR of 2.97% to attain a value of US$150.524 billion by 2027.

The ageing population in countries like the United States and Canada is the major driver of the antirheumatic drug market in this region. According to the United States Census Bureau, all baby boomers will be older than age 65 by 2030, expanding the size of the older population such that 1 in every 5 residents will be at retirement age. According to the data provided by the Government of Canada, almost one in seven Canadians was over 65 in 2012, which is projected to rise to nearly one in four by 2030. Since arthritis problems are more common in this age group, this projection of the geriatric population will continue to drive the antirheumatic drug market in North America throughout the forecast period.

The presence of major market players in the country also contributes to the market growth of antirheumatic drugs in the U.S. FDA (Food and Drug Administration) has approved many antirheumatic drugs in recent past years, particularly in 2017, which is also boosting the country’s market growth. For example, abaloparatide was approved in April 2017 for post-menopausal women with osteoporosis and a high risk of fracture. In August 2019, the FDA approved AbbVie’s RINVOQ®, a 15 mg, once-daily oral JAK (Janus Kinase) inhibitor for the treatment of moderate to severe rheumatoid arthritis in adults with zero tolerance or inadequate response to methotrexate (MTX-IR). In Canada as well, AbbVie has got approval for its RINVOQ® from Health North America. As such, the market for anti-rheumatic drugs in North America will continue to grow at a substantial rate during the forecast period. The availability of over-the-counter (OTC) drugs to treat rheumatic diseases is further boosting the market growth of the antirheumatic drug market in North America.

The North American Antirheumatic Drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis, rheumatoid arthritis, gout, lupus, and others. By type of molecule, the North American anti-rheumatic drug market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC). By country, the North American antirheumatic drug market is segmented into the United States, Canada, and Mexico. 

Key Developments in the Market:

• In April 2022, AbbVie announced the approval of its RINVOQ by the US Food and Drug Administration for the treatment of active ankylosing spondylitis in patients who are intolerant or show inadequate response to tumour necrosis factor. This development offers an alternative and effective treatment for patients unresponsive to TNF blockers.
• In October 2021, US FDA approved the first-ever interchangeable biosimilar to Humaria, Cyltezo. Interchangeable biosimilars aid in enhancing access to treatment alternatives for patients with severe medical conditions. The said drug was approved for the treatment of moderate to severely active rheumatoid arthritis and active ankylosing spondylitis, among a few other conditions in adults.
• In September 2020, Pfizer announced the approval of XEJANZ for the treatment of adolescents and children two years and older with active polyarticular course juvenile idiopathic arthritis. Two formulations, an oral solution and a tablet were approved. XELJANZ is the first and only JAK inhibitor to be approved in the US for the treatment of pcJIA.

COVID-19 Insights:

COVID-19 had a significant impact on the antirheumatic drugs market. The growing number of adolescents and adult patients with multiple types of rheumatic diseases in the North American countries is driving the demand for the drugs in the region. However, owing to the surge in active cases and the enforcement of drastic measures like lockdown and social distancing, amid pandemic led to the closure of many production facilities, decreasing productivity. Furthermore, border restrictions further affected the imports and exports in the regions, disrupting the supply chain. Such factors slowed down the growth of the market amid the pandemic.

Segmentation

• By Type of Disease
  • Osteoarthritis
  • Rheumatoid Arthritis
  • Gout
  • Lupus
  • Others
• By Drug Class
  • Disease-modifying Anti-Rheumatic Drugs (DMARDs)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • JAK inhibitor
  • Others
• By Sales Channel
  • Prescription
  • Over-The-Counter (OTC)

AbbVie Inc.

Amget Inc.

Johnson and Johnson

Pfizer Inc.

GlaxoSmithKline plc

Merck & Co., Inc.

Eli Lilly and Company

Novartis AG

Celgene Corporation (Bristol-Myers Squibb)